KCND2

A-type voltage-gated potassium channel KCND2 · Q9NZV8 · KCND2 on Sugi Atlas →

1,124 patent compounds predicted against KCND2, 850 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Vernakalant (SCHEMBL439144)	1.00	5/20
Vernakalant (SCHEMBL439679)	1.00	5/20
Vernakalant (SCHEMBL439706)	1.00	5/20
Vernakalant (SCHEMBL441030)	1.00	5/20
Vernakalant (SCHEMBL441544)	1.00	5/20
Vernakalant (SCHEMBL441926)	1.00	5/20
Vernakalant (SCHEMBL442387)	1.00	5/20
Vernakalant (SCHEMBL443797)	1.00	5/20
Vernakalant (SCHEMBL1762185)	1.00	5/20
Vernakalant (SCHEMBL1762326)	1.00	5/20
Vernakalant (SCHEMBL3338844)	1.00	5/20
Vernakalant (SCHEMBL4615829)	1.00	5/20
Vernakalant (SCHEMBL6276115)	1.00	5/20
Vernakalant (SCHEMBL409711)	0.98	5/20
Vernakalant (SCHEMBL409715)	0.98	5/20
Vernakalant (SCHEMBL410062)	0.98	5/20
Vernakalant (SCHEMBL410066)	0.98	5/20
Vernakalant (SCHEMBL411046)	0.98	5/20
Vernakalant (SCHEMBL411090)	0.98	5/20
Vernakalant (SCHEMBL411259)	0.98	5/20

Clinical trials — most relevant to KCND2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery	PHASE4	RECRUITING
Mutation-specific Therapy for the Long QT Syndrome	PHASE2	COMPLETED
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy	PHASE1/PHASE2	RECRUITING
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients	PHASE2	COMPLETED
4-Aminopyridine in Episodic Ataxia Type 2	PHASE2	WITHDRAWN
Pathophysiology Based Therapy of Early Onset Epileptic Encephalopathies	PHASE2	WITHDRAWN
N-of-1 in ATS and MEPPC	PHASE2	NOT_YET_RECRUITING
Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss	PHASE2	COMPLETED
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK	PHASE1	COMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Characteristics of Andersen-Tawil Syndrome	nan	COMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism	nan	COMPLETED
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development	nan	RECRUITING
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy	nan	UNKNOWN
Qatar Cardiovascular Biorepository of AF Patients	nan	UNKNOWN
Metabolism of Patients With Genetically Caused Cardiac Arrhythmia	nan	UNKNOWN
The Effects of the Anti Nausea Drugs Droperidol and Ondansetron on the Way the Heart Recovers Between Beats	nan	COMPLETED
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation	nan	UNKNOWN
The Effects of the Anesthetic Drug Propofol on the Way the Heart Recovers Between Beats	nan	COMPLETED
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.	nan	UNKNOWN
Development of an Artificial Intelligence Algorithm to Detect Pathological Repolarization Disorders on the ECG and the Risk of Ventricular Arrhythmias	nan	RECRUITING
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA)	nan	UNKNOWN
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services	nan	UNKNOWN
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases	nan	UNKNOWN
Central and Peripheral Nervous System Changes as Markers of Disease Progression in Multiple Sclerosis	nan	COMPLETED
Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome	nan	RECRUITING
Comparison Between Epinephrine and Exercise Test in QT Long Syndrome Patients	nan	UNKNOWN
Characteristics of Episodic Ataxia Syndrome	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a KCND2 binder may also engage these)

Protein	Name	Similarity
Q8HYZ1	—	1.000	Q8HYZ1 →
Q9Z0V2	—	1.000	Q9Z0V2 →
Q63881	—	1.000	Q63881 →
P59995	—	1.000	P59995 →
Q9Z0V1	—	1.000	Q9Z0V1 →
KCND3	A-type voltage-gated potassium channel KCND3	1.000	landscape →
Q62897	—	1.000	Q62897 →
Q9TTT5	—	1.000	Q9TTT5 →
Q52PG9	—	0.994	Q52PG9 →
P17971	—	0.993	P17971 →
P25122	—	0.991	P25122 →
Q03719	—	0.991	Q03719 →
P17972	—	0.987	P17972 →
P15388	—	0.987	P15388 →
P59994	—	0.986	P59994 →
Q9NSA2	—	0.986	Q9NSA2 →
KCNB1	Potassium voltage-gated channel subfamily B member 1	0.983	landscape →
Q63734	—	0.983	Q63734 →
Q8BZN2	—	0.983	Q8BZN2 →
Q9XXD1	—	0.983	Q9XXD1 →
Q03717	—	0.983	Q03717 →
KCNC1	Voltage-gated potassium channel KCNC1	0.982	landscape →
Q95167	—	0.982	Q95167 →
Q03721	—	0.982	Q03721 →
A6H8H5	—	0.981	A6H8H5 →
Q9MZ19	—	0.981	Q9MZ19 →
Q14B80	—	0.980	Q14B80 →
O18868	—	0.980	O18868 →
P22462	—	0.980	P22462 →
Q63099	—	0.979	Q63099 →